Paul Ratner

Summary

Publications

  1. doi request reprint Once-daily treatment with beclomethasone dipropionate nasal aerosol does not affect hypothalamic-pituitary-adrenal axis function
    Paul H Ratner
    Sylvana Research Associates, San Antonio, Texas 78229, USA
    Ann Allergy Asthma Immunol 109:336-41. 2012
  2. doi request reprint Pharmacokinetic profile of beclomethasone dipropionate hydrofluoroalkane after intranasal administration versus oral inhalation in healthy subjects: results of a single-dose, randomized, open-label, 3-period crossover study
    Paul H Ratner
    Sylvana Research Associates, San Antonio, TX 78229, USA
    Clin Ther 34:1422-31. 2012
  3. doi request reprint An investigation of the pharmacokinetics, pharmacodynamics, safety, and tolerability of ciclesonide hydrofluoroalkane nasal aerosol in healthy subjects and subjects with perennial allergic rhinitis
    Paul Ratner
    Sylvana Research Institute, 7711 Louis Pasteur Drive, Suite 406, San Antonio, TX 78229, USA
    Pulm Pharmacol Ther 24:426-33. 2011
  4. doi request reprint Evaluation of the efficacy and safety of ciclesonide hydrofluoroalkane nasal aerosol, 80 or 160 μg once daily, for the treatment of seasonal allergic rhinitis
    Paul Ratner
    Sylvana Research Associates, San Antonio, Texas 78229, USA
    Ann Allergy Asthma Immunol 105:471-9. 2010
  5. doi request reprint Mometasone furoate nasal spray is safe and effective for 1-year treatment of children with perennial allergic rhinitis
    Paul H Ratner
    Sylvana Research Associates, San Antonio, TX 78229, USA
    Int J Pediatr Otorhinolaryngol 73:651-7. 2009
  6. ncbi request reprint Ciclesonide and beclomethasone dipropionate coadministration: effect on cortisol in perennial allergic rhinitis
    Paul Ratner
    Altana Pharma US, Florham Park, New Jersey, USA
    J Asthma 44:629-33. 2007
  7. doi request reprint Lack of effect on adult and adolescent hypothalamic-pituitary-adrenal axis function with use of fluticasone furoate nasal spray
    Deepen Patel
    Allied Research International Inc, Mississauga, Ontario, Canada
    Ann Allergy Asthma Immunol 100:490-6. 2008
  8. ncbi request reprint Comparison of cetirizine-pseudoephedrine and placebo in patients with seasonal allergic rhinitis and concomitant mild-to-moderate asthma: randomized, double-blind study
    Robert A Nathan
    Asthma and Allergy Associates, Colorado Springs 80907, USA
    Ann Allergy Asthma Immunol 97:389-96. 2006
  9. ncbi request reprint Fexofenadine hydrochloride, 180 mg, exhibits equivalent efficacy to cetirizine, 10 mg, with less drowsiness in patients with moderate-to-severe seasonal allergic rhinitis
    Frank Hampel
    Central Texas Health Research, New Braunfels, Texas 78130, USA
    Ann Allergy Asthma Immunol 91:354-61. 2003
  10. ncbi request reprint Efficacy and safety of desloratadine 5 mg once daily in the treatment of chronic idiopathic urticaria: a double-blind, randomized, placebo-controlled trial
    Eugene Monroe
    Advanced Healthcare, Milwaukee Medical Clinic, WI 53209 0996, USA
    J Am Acad Dermatol 48:535-41. 2003

Detail Information

Publications10

  1. doi request reprint Once-daily treatment with beclomethasone dipropionate nasal aerosol does not affect hypothalamic-pituitary-adrenal axis function
    Paul H Ratner
    Sylvana Research Associates, San Antonio, Texas 78229, USA
    Ann Allergy Asthma Immunol 109:336-41. 2012
    ..Intranasal corticosteroids are effective in controlling allergic rhinitis (AR) symptoms; however, chronic administration of corticosteroids may suppress hypothalamic-pituitary-adrenal (HPA)-axis function...
  2. doi request reprint Pharmacokinetic profile of beclomethasone dipropionate hydrofluoroalkane after intranasal administration versus oral inhalation in healthy subjects: results of a single-dose, randomized, open-label, 3-period crossover study
    Paul H Ratner
    Sylvana Research Associates, San Antonio, TX 78229, USA
    Clin Ther 34:1422-31. 2012
    ..Recently, a hydrofluoroalkane (HFA)-propelled nasal aerosol formulation of BDP was developed to treat allergic rhinitis. However, the pharmacokinetic profile of BDP HFA nasal aerosol has not been previously investigated...
  3. doi request reprint An investigation of the pharmacokinetics, pharmacodynamics, safety, and tolerability of ciclesonide hydrofluoroalkane nasal aerosol in healthy subjects and subjects with perennial allergic rhinitis
    Paul Ratner
    Sylvana Research Institute, 7711 Louis Pasteur Drive, Suite 406, San Antonio, TX 78229, USA
    Pulm Pharmacol Ther 24:426-33. 2011
    ..Both doses of CIC-HFA were well tolerated without significant effect on cortisol levels...
  4. doi request reprint Evaluation of the efficacy and safety of ciclesonide hydrofluoroalkane nasal aerosol, 80 or 160 μg once daily, for the treatment of seasonal allergic rhinitis
    Paul Ratner
    Sylvana Research Associates, San Antonio, Texas 78229, USA
    Ann Allergy Asthma Immunol 105:471-9. 2010
    ..A new nasal aerosol formulation of ciclesonide containing a hydrofluoroalkane propellant delivered via a metered-dose inhaler (CIC-HFA) is currently in clinical development as a potential treatment for AR...
  5. doi request reprint Mometasone furoate nasal spray is safe and effective for 1-year treatment of children with perennial allergic rhinitis
    Paul H Ratner
    Sylvana Research Associates, San Antonio, TX 78229, USA
    Int J Pediatr Otorhinolaryngol 73:651-7. 2009
    ..In this study, the long-term safety and efficacy of mometasone furoate nasal spray (MFNS) were assessed in children with PAR...
  6. ncbi request reprint Ciclesonide and beclomethasone dipropionate coadministration: effect on cortisol in perennial allergic rhinitis
    Paul Ratner
    Altana Pharma US, Florham Park, New Jersey, USA
    J Asthma 44:629-33. 2007
    ..001), demonstrating that further cortisol suppression was possible. This study suggests that intranasal ciclesonide can be used with an inhaled corticosteroid without increased cortisol suppression...
  7. doi request reprint Lack of effect on adult and adolescent hypothalamic-pituitary-adrenal axis function with use of fluticasone furoate nasal spray
    Deepen Patel
    Allied Research International Inc, Mississauga, Ontario, Canada
    Ann Allergy Asthma Immunol 100:490-6. 2008
    ..Intranasal corticosteroids are recommended as first-line therapy for allergic rhinitis (AR), and because of their pharmacologic class, hypothalamic-pituitary-adrenal (HPA) axis function is evaluated...
  8. ncbi request reprint Comparison of cetirizine-pseudoephedrine and placebo in patients with seasonal allergic rhinitis and concomitant mild-to-moderate asthma: randomized, double-blind study
    Robert A Nathan
    Asthma and Allergy Associates, Colorado Springs 80907, USA
    Ann Allergy Asthma Immunol 97:389-96. 2006
    ..Allergic rhinitis (AR) and asthma are common concurrent conditions...
  9. ncbi request reprint Fexofenadine hydrochloride, 180 mg, exhibits equivalent efficacy to cetirizine, 10 mg, with less drowsiness in patients with moderate-to-severe seasonal allergic rhinitis
    Frank Hampel
    Central Texas Health Research, New Braunfels, Texas 78130, USA
    Ann Allergy Asthma Immunol 91:354-61. 2003
    ..Previous studies have shown that fexofenadine and cetirizine effectively relieve symptoms of seasonal allergic rhinitis (SAR)...
  10. ncbi request reprint Efficacy and safety of desloratadine 5 mg once daily in the treatment of chronic idiopathic urticaria: a double-blind, randomized, placebo-controlled trial
    Eugene Monroe
    Advanced Healthcare, Milwaukee Medical Clinic, WI 53209 0996, USA
    J Am Acad Dermatol 48:535-41. 2003
    ..Chronic idiopathic urticaria (CIU) has a major impact on patient well-being. Antihistamines are the first-line treatment for CIU; however, some cause sedation...